Asundexian: Bayer Shares Rise To Highest Since July 2020: Bayer On Potential Blockbuster Anticoagulant With Positive Phase 2b Results | news

Asundexian is being studied as a new treatment option for the prevention of thrombosis.

As announced by the DAX group, data from the so-called PACIFIC-AF study had shown that patients with atrial fibrillation and risk of stroke had significantly lower bleeding rates after administration of Asundexian compared to the blood thinner apixaban. In patients receiving Asundexian, bleeding rates for the primary endpoint of “clinically relevant non-major bleeding” were 67% lower than with apixaban, an approved anticoagulant drug manufactured by Bayer’s competitors.

Both 20 mg and 50 mg doses of Asundexian were well tolerated, and both doses caused lower bleeding rates compared to apixaban, the drug company said. At the same time, a significant inhibition of FXIa, an important factor in the blood coagulation process, was achieved.

Atrial fibrillation is the most common sustained cardiac arrhythmia with the possibility of blood clots. These can break off and travel to the brain, which can lead to a stroke.

According to Bayer, the study was planned as a phase 2 dose-finding study. A phase 3 efficacy study will be decided later this year after analysis of data from the safety study.

At the same time, Bayer presented the study results at the 71st conference of the American College of Cardiology and published them in The Lancet.

Bayer shares at highs since July 2020 after positive study data

Positive study data on drug candidate Asundexian pushed Bayer shares to another high since the summer of 2020 on Monday. Several analysts were positive. Barclays expert Emily Field even made a new recommendation with “Overweight” and also raised the price target.

Shares in the agar chemical and pharmaceutical group rose in early trading as much as 3.4 percent to 65.14 euros and were among the highest values ​​on the DAX. More recently, it is still up 2.33 percent at 64.49 euros.

A market expert praised the new thrombosis prevention drug in the study that examined safety and optimal dosage. Analyst Alistair Campbell of investment house Liberum now sees a good chance that if the active ingredient is approved, it could be an even bigger hit than blockbuster Xarelto, which dumps billions in sales into Bayer’s coffers every year. anus.

According to Campbell, Asundexian is also important to Leverkusen because it is currently developing without a partner. Therefore, sales with it would not have to be shared, unlike Xarelto, which Bayer markets outside the US, but within the important US market, competitor Johnson & Johnson.

JPMorgan analyst Richard Vosser highlighted the lower risk of bleeding compared to the Eliquis blood thinner from competitors Bristol-Meyers Squibb (BMS) and Pfizer. “Overall, we consider Asundexian’s bleeding profile to be significantly better than Eliquis’s,” he wrote. This should significantly increase investor confidence in Bayer’s drug candidates. This should “lead to a significant improvement in average analyst estimates,” he hopes.

FRANKFURT (Dow Jones / dpa-AFX)

Selected leverage products at BayerWith knockouts, speculative investors can participate disproportionately in price movements. Simply select the desired lever and we’ll show you the right products at Bayer

Leverage must be between 2 and 20

No data

More Bayer news

Image sources: Bayer, 360b / Shutterstock.com

Leave your vote

Leave a Comment

Log In

Forgot password?

Forgot password?

Enter your account data and we will send you a link to reset your password.

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

Add to Collection

No Collections

Here you'll find all collections you've created before.